Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease

Chimerix

Status

Conditions: Adenovirus

Treatments: Drug: Brincidofovir

Study type: Expanded Access

Funder types: Industry

Identifiers

NCT02596997

CMX001-351

Details and patient eligibility

About

Provide patients with serious AdV infection or disease access to treatment with BCV.

Sex: All

Ages: 2+ months old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Confirmed serious AdV infection based on clinical symptoms and laboratory testing showing AdV in the blood or other bodily fluids
• Able to swallow medication, either tablet or liquid

Exclusion criteria

• Previous dosing with Brincidofovir
• If female, not pregnant or trying to become pregnant